La ataxia de Friedreich es una enfermedad rara neurodegenerativa que se diagnostica antes de los 25 años. En España afecta a unas 2.000 personas. El ensayo FRAMES iniciará el reclutamiento de pacie...
Read moreThe funding round was led by Fund+, joined by SFPI-FPIM, S.R.I.W. and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi V...
Read moreEl primer paciente con esta enfermedad rara que ha iniciado el tratamiento con MIN-102 ha sido en el Hospital Vall d'Hebron de Barcelona. El estudio, denominado ADVANCE, reclutará en total a 100 paci...
Read moreMinoryx Therapeutics – a drug development company specialized in the discovery and development of new drugs for orphan diseases, which has R& D laboratories at the Barcelona Science Park– announce...
Read moreMIN-102 targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need. Orphan drug status for MIN-102 has now been granted by both the FDA and the E...
Read moreMIN-102 is a selective PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept in multiple animal models. Phase I studi...
Read moreMIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...
Read moreYsios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...
Read more